Possibilities of the analgesic action of botulinum therapy in clinical practice

  • 作者: Orlova O.R.1,2, Alekseeva A.Y.1,2, Konovalova Z.N.2, Kostenko E.V.3,4, Krasavina D.A.5,6, Mingazova L.R.7, Soykher M.I.7,8
  • 隶属关系:
    1. «I.M. Sechenov First Moscow Medical University» FSAEI of the of the Ministry of Healthcare of Russia (Sechenov University)
    2. Central Institute of botulinum therapy and actual neurology
    3. N.I. Pirogov Russian National Research Medical University FSAEI HE of the Ministry of Healthcare of Russia
    4. «Moscow Scientific and Practical Center for medical rehabilitation, restorative and sports medicine» Autonomous Public Health Care Institution of the Moscow Healthcare Department
    5. FSBEI of Higher Education «St. Petersburg State Pediatric Medical University» of the Ministry of Healthcare of Russia
    6. FSBI FVE at the «St. Petersburg Institute for the Advanced Training of Expert Doctors» of the Ministry of Labor of Russia
    7. Center for interdisciplinary dentistry and neurology
    8. «Moscow Regional Dental Clinic» Autonomous Public Health Care Institution
  • 期: 编号 7-8 (2018)
  • 页面: 52-56
  • 栏目: Articles
  • URL: https://journals.eco-vector.com/2412-4036/article/view/288152
  • ID: 288152

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article deals with the problem of pain syndromes in various neurological disorders: cervical dystonia, chronic migraine, myofascial pain syndrome, bruxism. It contains the data of clinical studies, as well as systematic reviews, justifying the effectiveness and safety of botulinum therapy for these diseases and conditions. Data on the antinociceptive action of type A botulinum neuroprotein are introduced, and new areas of its clinical application are indicated.

全文:

受限制的访问

作者简介

Olga Orlova

«I.M. Sechenov First Moscow Medical University» FSAEI of the of the Ministry of Healthcare of Russia (Sechenov University); Central Institute of botulinum therapy and actual neurology

Email: ororlova@yandex.ru
MD, professor of the Department of nervous diseases of the Institute of Professional Education; President of the Interregional Public Organization of botulinum therapy specialists (MOOSBT), head

Anna Alekseeva

«I.M. Sechenov First Moscow Medical University» FSAEI of the of the Ministry of Healthcare of Russia (Sechenov University); Central Institute of botulinum therapy and actual neurology

6th year student of the Faculty of General Medicine

Zagidat Konovalova

Central Institute of botulinum therapy and actual neurology

PhD, a member of the MOOSBT.

Elena Kostenko

N.I. Pirogov Russian National Research Medical University FSAEI HE of the Ministry of Healthcare of Russia; «Moscow Scientific and Practical Center for medical rehabilitation, restorative and sports medicine» Autonomous Public Health Care Institution of the Moscow Healthcare Department

MD, associate professor of the Department of public Health and Healthcare, Healthcare Economics of Pediatric Faculty; head of a branch

Diana Krasavina

FSBEI of Higher Education «St. Petersburg State Pediatric Medical University» of the Ministry of Healthcare of Russia; FSBI FVE at the «St. Petersburg Institute for the Advanced Training of Expert Doctors» of the Ministry of Labor of Russia

MD, professor of the Department of surgical diseases of pediatric age; head of the Department of traumatology and orthopedics, medical and social assessment, prosthetics and rehabilitation

Leniza Mingazova

Center for interdisciplinary dentistry and neurology

PhD, a member of the MOOSBT

Marina Soykher

Center for interdisciplinary dentistry and neurology; «Moscow Regional Dental Clinic» Autonomous Public Health Care Institution

PhD, associate professor of the Department of Pediatric Dentistry and Orthodontics, Chief Doctor of «Moscow Regional Dental Clinic» State Autonomous Healthcare Institution

参考

  1. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinumtoxin type A. Neuro Toxicology. 2005; 26:785-793.
  2. Goadsby P.J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993; 33: 48-56.
  3. Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003; 43(Suppl 1): 9-15.
  4. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005; 26(5): 785-93. Cui M., Khanijou S., Rubino J., Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain, 2004; 107(1-2): 125-133.
  5. Dressler D., Saberi F.A., Barbosa E.R. Botulinum toxin: mechanisms of action. ArqNeuropsiquiatr. 2005; 63: 180-5.
  6. Durham P.L., Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache 2011; 51(10): 1573-7.
  7. Gazerani P., Staahl C., Drewes A.M., Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006; 122(3): 315-25.
  8. Gazerani P., Pedersen N.S., Staahl C. et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009; 141(1-2): 60-9.
  9. Aoki K.R. Evidence for antinociceptive activity of botulinumtoxin type A in pain management. Headache 2003; 43 (Suppl 1): 9-15.
  10. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005; 26(5): 785-93.
  11. Gazerani P., Staahl C., Drewes A.M., Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006; 122(3): 315-25.
  12. Артеменко А.Р., Орлова О.Р. Ботулинический токсин типа А: расширение возможностей терапии первичных головных болей. Врач. 2007; 5: 40-43.
  13. Орлова О.Р. Диссертация на соискание ученой степени доктора медицинских наук: Фокальные дистонии: клиника, патогенез, лечение с использованием токсина ботулизма. Москва. 2000 г.
  14. Stamelou M., Edwards M., Hallett M., Bhatia K. The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain. 2011; 135(6): 1668-81.
  15. Fiorio M., Gambarin M., Valente E.M., Liberini P., Loi M., Cossu G. et al. The basal ganglia are hyperactive during the discrimination of tactile stimuli in writer's cramp. Brain 2006; 129: 2697-708.
  16. Camargo C.H., Teive H.A., Becker N., Baran M.H., Scola R.H., Werneck L.C. Cervical dystonia: clinical and therapeutic features in 85 patients. Arq Neuropsiquiatr. 2008; 66(1): 15-21.
  17. Eichenseer S.R., Stebbins G.T., Comella C.L. Beyond a motor disoder: a prospective evaluation of sleep quality in cervical dystonia. Park Relat. Disord. 2014; 20: 405-8.
  18. Charles P.D.1, Adler C.H., Stacy M., Comella C., Jankovic J., Manack Adams A., Schwartz M., Brin M.F. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014; 261: 1309-1319.
  19. Gobel H., Heinze A., Heinze-Kuhn K., Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001; 91: 195-199.
  20. Blumenfeld A., Silberstein S.D., Dodick D.W., Aurora S.K., Turkel C.C., Binder W.J. Method of injection of OnabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010; 50: 1406-1418.
  21. Blumenfeld A., Stark R., Manack Adams A., Orejudos A., Aurora S. Efficacy and safety of OnabotulinumtoxinA in an open-label study for the prophylactic treatment of chronic migraine in adult patients: COMPEL (Abstract 030). 5th European Headache and Migraine Trust International Congress - EHMTIC; 15 to 18 September 2016; Glasgow, UK.
  22. Shah J.P., Danoff J.V., Desai M.J., Parikh S., Nakamura L.Y., Phillips T.M., Gerber L.H. Biochemicals associated with pain and inflammation are elevated in sites near to and remote from active myofascial trigger points. Arch Phys Med Rehabil. 2008; 89(1): 16-23.
  23. Gerwin R. Myofascial pain syndrome: here we are, where must we go? J. Musculoskeletal Pain. 2010; 18: 329-347.
  24. Göbel H., Heinze A., Reichel G., Hefter H., Benecke R. Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain. 2006; 125: 82-88 [PubMed].
  25. Коновалова З.Н., Орлова О.Р. Миофасциальные болевые синдромы: лечение локальными инъекциями ботулотоксина типа А (Релатокс). Метаморфозы. 2015; 10: 82-86 с.
  26. Freund B.J., Schwartz M. Use of botulinum toxin in chronic whiplash-associated disorder. Clin J Pain. 2002; 18(6 Suppl): S163-S168 [PubMed].
  27. Применение препарата Диспорт® (БТА) для лечения локального мышечного гипертонуса при фокальных дистониях, спастичности и других мышечно-тонических синдромах. Метаморфозы. 2015; 5: 70-80.
  28. Орлова О.Р., Коновалова З.Н., Алексеева А.Ю., Мингазова Л.Р., Сойхер М.И. Взаимосвязь бруксизма и болевой дисфункции височно-нижнечелюстного сустава. РМЖ. 2017; 24: 1760-1763.
  29. Орлова О.Р., Алексеева А.Ю., Мингазова Л.Р., Коновалова З.Н. Бруксизм как неврологическая проблема (обзор литературы). Нервно-мышечные болезни. 2018; 8(1): 20-27.
  30. Ella B., Ghorayeb I., Burbaud P., Guehl D. Bruxism in movement disorders: a comprehensive review. J Prosthodont. 2017; 26(7):.599-605.
  31. Guaita M., Högl B. Current treatments of bruxism. Curr Treat Options Neurol. 2016; 18(2): 10.
  32. Сойхер М.И., Мамедов А.А., Орлова О.Р., Фомин И.В. Бруксизм: преодоление междисциплинарной разобщенности. Перспективы развития миофункциональной терапии в медицине : материалы международного конгресса (Москва, 2 марта 2018 г.) [под ред. Н.А. Касимовской]. ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский университет). М.: издательство Первого МГМУ имени И.М. Сеченова, 2018. С.119-125.
  33. Bentsianov B., Zalvan C., Blitzer A. Noncosmetic uses of botulinum toxin. ClinDermatol. 2004; 22(1): 82-88.
  34. Guarda-Nardini L., Manfredini D., Salamone M., Salmaso L., Tonello S., Ferronato G. Efficacy of Botulinum Toxin in Treating Myofascial Pain in Bruxers: A Controlled Placebo Pilot Study. The Journal of Craniomandibular Practice. 2008; 26(2): 1-10.
  35. Bogucki Z.A., Kownacka M. Clinical Aspects of the Use of Botulinum Toxin Type A in the Treatment of Dysfunction of the Masticatory System. AdvClinExp Med. 2016; 25(3): 569-73.
  36. Сойхер М.И., Орлова О.Р., Сойхер М.Г., Мингазова Л.Р., Писаренко И.К., Фомин И.В., Шершнева Д.В. Терапевтическая эффективность применения ботулинического токсина типа А (нейропротеин) при симптоматическом лечении бруксизма. Медицинский алфавит. Стоматология. 2018; 24(3): 61-69.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2018
##common.cookie##